TTF-1 and immune checkpoint therapy in non-small cell lung cancer

10-12). However, as the current standard of care therapy for patients with advanced non-squamous NSCLC without a targetable mutation has changed in recent years to include an ICI, it has remained unknown if TTF-1 expression still affects patient outcomes when treated with modern chemoimmunotherapeutic regimens. Ibusuki et al. begin to address this question through a retrospective analysis of 122 patients with advanced non-squamous NSCLC treated in the first-line setting with a pemetrexed-containing chemoimmunotherapy regimen at four different institutions in Japan (13). Here the authors demonstrate significantly improved progression-free survival (PFS) amongst patients with TTF-1-positive non-squamous NSCLC compared to those with TTF-1-negative disease